SCH 211803

Drug Profile

SCH 211803

Latest Information Update: 19 Sep 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Class Antidementias; Neuroprotectants
  • Mechanism of Action Muscarinic M2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 07 Apr 2003 Data presented at the 225th American Chemical Society Meeting (225th-ACS) have been added to the pharmacokinetics section
  • 15 Mar 2002 Discontinued - Phase-I for Alzheimer's disease in USA (unspecified route)
  • 26 Apr 2001 Phase-I clinical trials for Alzheimer's disease in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top